Companies › Dong-A ST
4 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 4, 1 Phase 3; Oncology, Gastroenterology, Metabolic and endocrine; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DA-9701-R | – | Phase 4 | Functional Dyspepsia | Oct 2027 |
| DA5221-T SGLT-2 inhibitor | SLC5A2 | Phase 3 | Type 2 Diabetes | – |
| DA-3501 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 1 | Gastric (Stomach) Cancer | Feb 2028 |
| DA-4505 | – | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Oct 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06290349 | DA5221-T | Phase 3 | Type 2 Diabetes | Metabolic and endocrine | Sep 2025 |
| NCT07686679 | DA-9701-R | Phase 4 | Functional Dyspepsia | Gastroenterology | Oct 2027 |
| NCT07481357 | DA-3501 | Phase 1 | Gastric (Stomach) Cancer | Oncology | Feb 2028 |
| NCT06293651 | DA-4505 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Oncology | Oct 2029 |
Biokin (Shanghai) Biopharmaceutical Hangzhou Sumgen Biotech LaNova Medicines Zhejiang Xuanzhu Biopharmaceutical InxMed (Shanghai)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.